INTRAGASTRIC BALLOONS, DUODENAL MUCOSAL RECELLULARIZATION/RESURFACING, ELECTROPORATION, RF VAPOR ABLATION, AND ENDOSCOPIC SLEEVE GASTROPLASTY

BASIC INFORMATION

Date & Time: 31 March 2026, 12:54 PM IST

Lecture Handout Prepared from the Teaching Session by: Dr. R. K. Mishra

SUMMARY

This consolidated lecture handbook, prepared on 31 March 2026 at 12:54 PM IST, synthesizes the SAGES RAFT webinar orientation and focused sessions on endobariatric and endometabolic therapies. It frames the Society of American Gastrointestinal and Endoscopic Surgeons’ mission and RAFT Committee’s training objectives, outlines membership structure and benefits, and presents evidence-based overviews of intragastric balloons (IGBs), duodenal mucosal recellularization/resurfacing (DMR), electroporation-based duodenal therapy, radiofrequency (RF) vapor ablation, and endoscopic sleeve gastroplasty (ESG). Core topics include device and technique fundamentals, clinical outcomes, safety, combination strategies with GLP-1 receptor agonists, patient selection, follow-up protocols, and adoption barriers such as reimbursement and procedural standardization. Technical pearls emphasize disciplined execution, full-thickness tissue capture (ESG), airway protection during IGB removal, strict ampullary avoidance during DMR, and structured multidisciplinary follow-up to sustain outcomes and mitigate complications.

KEY KNOWLEDGE POINTS

• SAGES RAFT Committee advances structured training for residents and fellows in minimally invasive and endoscopic surgery.

• The webinar focuses on endobariatric alternatives to Roux-en-Y gastric bypass: intragastric balloons, DMR, and ESG.

• SAGES membership provides access to Surgical Endoscopy, grants, leadership pathways, learning resources, and networking.

• Intragastric balloons yield predictable total body weight loss (~15–20% real-world) with low serious adverse event rates; technique dictates safety.

• DMR and related duodenal therapies target foregut mucosal dysregulation to improve glycemia and hepatic steatosis/fibrosis.

• Electroporation and RF vapor ablation are emerging duodenal modalities with favorable early efficacy and procedural efficiency.

• ESG delivers durable weight loss (~14–18% at 1–5 years) with low complication rates; combination with GLP-1 therapy enhances outcomes.

• Multidisciplinary follow-up and anticipatory pharmacotherapy around IGB explant reduce weight regain.

• Reimbursement and CPT code developments shape adoption; engineering simplification and standardized training are essential for scale.

INTRODUCTION

Endobariatric and endometabolic interventions have expanded therapeutic options for obesity and type 2 diabetes beyond traditional surgery. The foregut hypothesis, supported by weight-loss-independent glycemic improvements following Roux-en-Y gastric bypass, implicates proximal small intestinal mucosa and neurohormonal signaling in dysglycemia. Endoscopic therapies—IGBs, DMR, electroporation, RF vapor ablation, and ESG—offer minimally invasive strategies to modulate anatomy and physiology, addressing satiety control, caloric intake, and metabolic signaling. Within SAGES’s educational ecosystem, the RAFT Committee curates structured training and mentorship for trainees and early-career surgeons, connecting evidence, technique, safety, and professional development to foster competent adoption of these interventions.

LEARNING OBJECTIVES

• Describe the organizational framework and training mission of SAGES RAFT and the webinar program sequence.

• Summarize device landscapes, procedural principles, and clinical outcomes for IGBs, DMR/electroporation/RF vapor ablation, and ESG.

• Identify membership categories, benefits, adoption barriers, and strategies to sustain outcomes and manage complications.

CORE CONTENT

1. SAGES RAFT ORIENTATION AND PROFESSIONAL ECOSYSTEM

1.1 Committee Purpose and Educational Modality

The RAFT Committee supports residents and fellows through structured training, mentorship, and skills acquisition in minimally invasive and endoscopic surgery. The webinar modality emphasizes live faculty-led didactics with dedicated Q&A to maximize engagement and knowledge transfer.

1.2 Program Sequence and Faculty Focus

• Intragastric balloons: evidence, technique, and clinical integration.

• Duodenal mucosal resurfacing/recellularization and related duodenal therapies.

• Endoscopic sleeve gastroplasty: framework, technique, and adoption.

1.3 Mission, Values, and Membership

SAGES’s mission is to innovate, educate, and collaborate to improve patient care, with core values of inclusivity, innovation, service, excellence, and global community. Membership benefits include discounts for the annual meeting, webinars, online learning, access to Surgical Endoscopy, research grants and career awards, leadership pathways, and networking with >7,000 surgeons. Categories: Active (Canada/USA surgeons) and Candidate (residents/fellows in accredited programs).

2. INTRAGASTRIC BALLOONS (IGBs): EVIDENCE, TECHNIQUE, AND CLINICAL INTEGRATION

2.1 Device Landscape and Mechanisms

• Liquid-filled single balloons (e.g., FDA-approved Orbera) occupy gastric space to induce early satiety; typical adult fill volume is ≥500 mL (commonly 400–700 mL).

• Adjustable balloons (e.g., Spatz) allow titration of volume to manage intolerance or enhance efficacy.

• Swallowable polyurethane thin-film balloons (under U.S. investigation) deflate spontaneously at ~4 months and pass per rectum.

2.2 Procedural Technique

• Placement: Diagnostic endoscopy confirms suitability; position the balloon under direct vision; fill incrementally to target volume; confirm fundal positioning and free antrum; discharge same day.

• Removal: Endotracheal intubation is recommended for airway protection; fully aspirate balloon contents before extraction; maintain close apposition to the scope tip across the gastroesophageal junction; re-inspect for mucosal trauma. Lubrication with edible oils reduces friction and eases removal.

2.3 Outcomes and Evidence

• Real-world series (~41,186 cases): Mean TBWL ≈18.4%, adverse events 2.53%, early removal 2.22%, mortality 3 in 40,000.

• Randomized trials: Early meta-analyses show 5–10% TBWL, with newer devices approaching ~16% TBWL.

• Metabolic effects: Prospective data demonstrate improvements in MAFLD histology; FDA recognizes temporary control of fatty liver parameters.

2.4 Combination Strategies and Follow-Up

Concomitant or post-explant GLP-1 therapy augments weight loss and mitigates regain; randomized data support higher TBWL with balloon plus oral semaglutide versus balloon alone. Monthly multidisciplinary follow-up during indwell and intensified support around removal are critical.

2.5 Health Economics and Adoption

Historically cash-pay in the U.S.; CPT code established in 2023 enables potential reimbursement. Market growth is projected at ~10–12% CAGR to ~US$300 million by 2030, contingent on U.S. reimbursement and device availability.

3. DUODENAL MUCOSAL RE CELLULARIZATION/RESURFACING (DMR) AND FOREGUT-TARGETED ENDOLUMINAL THERAPIES

3.1 Pathophysiological Rationale

Chronic high-fat, high-carbohydrate exposure induces duodenal mucosal remodeling (increased cell mass, villous elongation, decreased crypt density), elevated enteroendocrine signals (including anti-incretin effects), and neuroinflammation around the enteric nervous system, perturbing gut–brain–pancreas axes. Bariatric surgery’s rapid, weight-independent glycemic normalization supports foregut-driven dysregulation.

3.2 DMR Principles and Technique

Hydrothermal ablation with submucosal lift (e.g., Revita catheter) delivers controlled mucosal injury, marching segmentally from distal D2 toward the ligament of Treitz while strictly avoiding the ampulla. Water at ~90°C is used for ablation followed by cooling; immediate blanching indicates effective treatment. Early outcomes show HbA1c reductions of ~0.8–1.2% maintained up to 24 months, with durability reported up to 48 months in select cohorts and concurrent improvements in hepatic steatosis/fibrosis and reduced insulin requirements.

3.3 Electroporation-Based Duodenal Therapy

A non-thermal, over-the-wire catheter applies electrical fields to induce apoptosis via membrane pore formation and ionic influx, aiming to avoid deep thermal injury. Early open-label studies report HbA1c reductions of ~0.9–1.6% with favorable safety (a 48-week cohort reported zero adverse events) and procedure times ≈1 hour.

3.4 RF Vapor Ablation

A through-the-scope nitinol dual-umbrella system creates a sealed chamber; saline is vaporized by RF energy to ablate mucosa. Pilot data show HbA1c reduction of ~1.2% at 12 weeks and ~0.8% at 24 weeks. Advantages include fluoroscopy-free delivery and potential extension into the proximal jejunum.

3.5 Indications, Populations, and Emerging Paradigm

Initial trials focus on type 2 diabetes due to regulatory and reimbursement pragmatics. An evolving strategy explores DMR as an off-ramp to sustain weight after GLP-1 cessation (e.g., REMAIN-1 design; early open-label observations suggest attenuation of early weight regain after stopping GLP-1s).

3.6 Adoption Challenges and Training

DMR’s value proposition includes reduced medication burden and outpatient execution with low adverse events. Engineering simplification (reducing reliance on fluoroscopy and guidewires) and standardized, reproducible technique are prerequisites for broad dissemination. Training difficulty is moderate, facilitated by prior experience in duodenal stenting and small bowel endoscopy.

4. ENDOSCOPIC SLEEVE GASTROPLASTY (ESG): FRAMEWORK, TECHNIQUE, OUTCOMES, AND ADOPTION

4.1 Conceptual Framework

A multimodal obesity care model integrates hardware (gastric capacity), software (hormonal milieu), guardrails (portion restriction and satiety), and operator (patient engagement). ESG provides hardware/guardrail interventions with partial hormonal effects and a low-complication profile.

4.2 Clinical Evidence and Indications

Five-year outcomes demonstrate ~15–18% TBWL with significant comorbidity improvement. Randomized and large comparative cohorts show ESG yields ~14% TBWL at three years versus ~19% with laparoscopic sleeve gastrectomy (LSG), with ESG exhibiting lower adverse event rates. In class I–II obesity, ESG is endorsed; in class III, surgery is preferred, but ESG is reasonable when surgery is declined or deferred.

4.3 Combination Therapy

ESG combined with GLP-1 agents enhances outcomes (reports up to ~25% TBWL at 12 months), exceeding ESG alone and outperforming GLP-1 monotherapy over long-term intervals.

4.4 Technical Principles

The Apollo OverStitch system is used for full-thickness, serosa-to-serosa bites to create a tubular, sleeve-like gastric configuration. Suture patterns (U, I, Z) are selected based on gastric morphology; bite spacing targets anterior–posterior 1.5–3 cm and proximal–distal 1–2 cm. Alignment of entry–exit points ensures uniform cinching and avoids “cheese-wire” tissue erosion by balanced tensioning.

4.5 Practice Integration and Training

Mastery follows a measurable learning curve (~10, 25, 50 cases), accelerated by high-volume endoscopy, structured courses, systematic video review, and proctoring. Right-hand economy during upper endoscopy—using wrist roll and scope wheels for rotation while reserving the right hand for insertion/withdrawal—supports bimanual therapeutic tasks. GERD rarely worsens after ESG; small-to-moderate hiatal hernias (~<4–5 cm) may be considered with careful selection recognizing non-repair of crural defects.

5. ANESTHETIC AND PHYSIOLOGICAL CONSIDERATIONS

• Intragastric balloon placement is typically performed under deep sedation without intubation; removal requires endotracheal intubation to mitigate aspiration risk, particularly in high-BMI patients or with retained gastric contents.

• Immediate post-balloon period (first 5–7 days) necessitates aggressive symptom management and hydration; antiemetic regimens may include aprepitant, with cautious use of scopolamine patches and adjunct dimenhydrinate.

6. COMPLICATIONS AND THEIR MANAGEMENT

6.1 Intraoperative

• IGB removal: Difficult balloon control is managed by complete aspiration, secure grasping (e.g., Raptor Grasper), lubrication, and maintained apposition to the scope tip during extraction.

• DMR: Ampullary injury risk is mitigated by strict anatomical awareness, submucosal lift, and distal-to-proximal marching that circumvents the ampulla.

• ESG: Avoid over-tensioning; ensure full-thickness capture to minimize tissue injury.

6.2 Early Postoperative

• IGB intolerance (nausea, vomiting, pain): Down-titrate adjustable balloons; administer potent antiemetics; initiate hydration; reassess if symptoms persist beyond 7 days.

• Balloon hyperinflation/deflation: Evaluate promptly; consider early removal.

• ESG: Transient discomfort or stricture-like muscular cramp may be managed with endoscopic balloon dilation.

6.3 Late Postoperative

• Balloon deflation and migration: Monitor for obstruction; intervene endoscopically or surgically as indicated.

• Balloon fungal colonization: Recognize material fragility at removal; consider antifungal measures where clinically warranted.

• ESG attenuation due to gastric accommodation: Reinforce behavioral and medical adjuncts; consider staged or adjunct interventions.

7. MEDICOLEGAL AND PATIENT SELECTION CONSIDERATIONS

• Obtain informed consent detailing device-specific risks (IGB hyperinflation/deflation, migration, intolerance; DMR investigational status and ampullary risks; ESG durability and potential attenuation).

• Document multidisciplinary counseling, dietary plans, and post-explant strategies for IGBs; align patient expectations with realistic TBWL ranges and adherence requirements.

• Screen for anatomical contraindications before DMR or balloon therapies; tailor ESG selection in the presence of hiatal hernia with explicit documentation of non-repair of crural defects.

• Integrate reimbursement strategy early; verify payer pathways and CPT coding where applicable; communicate potential out-of-pocket costs.

SURGICAL PEARLS

• Practical tips based on surgical experience:

  • IGB removal: Fully aspirate before extraction; keep the balloon closely apposed to the scope tip across the gastroesophageal junction; use edible oil lubrication to reduce friction.

  • DMR: Maintain strict ampullary avoidance; ensure robust submucosal lift; progress segmentally to minimize skip areas.

  • ESG: Capture full-thickness, serosa-to-serosa bites; align entry–exit points to ensure uniform cinching; apply balanced tension to avoid tissue strangulation.

  • Training: Build right-hand economy; use structured courses, video review, and proctoring to accelerate mastery.

• Common mistakes and how to avoid them:

  • IGB: Puncturing in unstable retroflexion; underfilling (<500 mL) reduces efficacy; neglecting pre-removal counseling predisposes to rapid regain.

  • DMR: Inadequate follow-up leads to preventable complications; insufficient submucosal lift increases injury risk.

  • ESG: Superficial, non–full-thickness bites compromise durability; inconsistent spacing produces uneven narrowing and failure.

ANESTHETIC AND PHYSIOLOGICAL CONSIDERATIONS

• Placement of IGBs: Deep sedation without intubation is typical.

• Removal of IGBs: Endotracheal intubation is recommended to prevent aspiration.

• Early post-balloon adaptation: Potent antiemetic therapy, structured hydration visits (including intravenous fluids at 48 hours), and close symptom monitoring are essential.

COMPLICATIONS AND THEIR MANAGEMENT

• Intraoperative:

  • IGB removal difficulty: Aspire contents thoroughly; use secure graspers and lubrication; maintain close scope-tip apposition.

  • DMR procedural injury: Avoid ampullary contact; use submucosal lift to protect deeper layers.

  • ESG tissue injury: Prevent over-tensioning; ensure full-thickness capture only.

• Early postoperative:

  • IGB intolerance and hyperinflation/deflation: Pharmacologic therapy, hydration, balloon down-titration (adjustable devices), and early removal if necessary.

  • ESG stricture-like cramp: Endoscopic balloon dilation with favorable response.

• Late postoperative:

  • IGB migration and obstruction: Prompt endoscopic or surgical intervention.

  • Balloon colonization and fragility: Gentle removal technique; antifungal consideration in selected cases.

  • ESG attenuation: Reinforce medical/lifestyle adjuncts; consider combination or staged interventions.

MEDICOLEGAL AND PATIENT SELECTION CONSIDERATIONS

• Explicitly counsel on risks, benefits, and realistic durability for each modality.

• Document adherence plans and follow-up pathways, particularly around IGB removal.

• Select candidates aligned with operator competency (e.g., DMR for endoscopists experienced in duodenal stenting).

• Integrate payer considerations and CPT coding in program design; track reductions in costly medications to support reimbursement discussions.

SUMMARY AND TAKE-HOME MESSAGES

• SAGES RAFT provides a structured training pathway and professional ecosystem for endobariatric and endometabolic therapies.

• IGBs, DMR/electroporation/RF vapor ablation, and ESG are complementary tools with distinct mechanisms, evidence, and technical demands.

• Rigorous technique, multidisciplinary follow-up, and strategic integration with pharmacotherapy are central to safety, durability, and adoption.

MULTIPLE CHOICE QUESTIONS (MCQs)

1. The RAFT Committee primarily focuses on which educational domain?

A. Hospital credentialing programs

B. Resident and fellow training in minimally invasive and endoscopic surgery

C. Industry sponsorship oversight

D. Billing and coding certification

Correct answer: B

2. The webinar’s overarching clinical theme is best described as:

A. Open bariatric surgery techniques

B. Endobariatric alternatives to Roux-en-Y gastric bypass

C. Colon cancer screening protocols

D. Thoracoscopic endocrine surgery

Correct answer: B

3. A liquid-filled FDA-approved intragastric balloon commonly used in practice is:

A. AspireAssist

B. Orbera

C. EndoBarrier

D. POSE

Correct answer: B

4. The primary mechanism of weight loss with intragastric balloons is:

A. Duodenal bypass and malabsorption

B. Gastric space occupancy leading to early satiety

C. Ghrelin suppression via fundal resection

D. Ileal transposition hormone shifts

Correct answer: B

5. Recommended airway management during intragastric balloon removal is:

A. Nasal cannula only

B. Laryngeal mask airway in all cases

C. Endotracheal intubation due to aspiration risk

D. No airway protection needed

Correct answer: C

6. A common technical error during IGB removal that should be avoided is:

A. Full aspiration prior to extraction

B. Lubrication to reduce friction

C. Puncturing the balloon in unstable retroflexion

D. Close apposition to scope tip during extraction

Correct answer: C

7. Real-world total body weight loss with IGBs across large cohorts is approximately:

A. 5%

B. 10%

C. 15–20%

D. >30%

Correct answer: C

8. DMR employs which core procedural safeguard to protect deeper layers?

A. Serosal injection before ablation

B. Submucosal lift to confine energy to mucosa/submucosa

C. Routine ampullary ablation

D. Pancreatic duct cannulation

Correct answer: B

9. Early clinical outcomes of DMR commonly show sustained HbA1c reductions of:

A. 0.1–0.3%

B. 0.4–0.6%

C. 0.8–1.2%

D. >2.5%

Correct answer: C

10. Electroporation-based duodenal therapy is characterized by:

A. Thermal coagulation and deep necrosis

B. Non-thermal apoptosis via membrane pore formation and ionic influx

C. Mechanical mucosal resection

D. Cryoablation of the ampulla

Correct answer: B

11. RF vapor ablation is operationally advantageous because it is delivered:

A. With mandatory fluoroscopy and guidewires

B. Through-the-scope without fluoroscopy

C. Via laparoscopic access

D. Using percutaneous catheters only

Correct answer: B

12. The SAGES membership benefit explicitly highlighted in the webinar is:

A. Automatic board certification

B. Free surgical instruments

C. Access to the journal Surgical Endoscopy

D. Personal malpractice coverage

Correct answer: C

13. ESG’s durability depends critically on:

A. Mucosal-only bites for flexibility

B. Full-thickness, serosa-to-serosa tissue apposition

C. Loose approximation to avoid tension

D. Exclusive use of absorbable sutures

Correct answer: B

14. Typical ESG total body weight loss reported at three to five years is:

A. 5–10%

B. ~14–18%

C. ~25–30%

D. >35%

Correct answer: B

15. In three-year comparative data, total body weight loss was approximately:

A. ESG ~19%, LSG ~14%

B. ESG ~14%, LSG ~19%

C. ESG ~25%, LSG ~30%

D. ESG ~8%, LSG ~12%

Correct answer: B

16. Combining ESG with GLP-1 therapy typically results in:

A. Lower weight loss than ESG alone

B. No change in outcomes

C. Enhanced weight loss approaching ~20–25% at 6–12 months

D. Excessive adverse events precluding use

Correct answer: C

17. A practical spacing recommendation for ESG bites is:

A. Anterior–posterior 0.5–1.0 cm; proximal–distal 0.2–0.5 cm

B. Anterior–posterior 1.5–3.0 cm; proximal–distal 1.0–2.0 cm

C. Anterior–posterior 3.5–5.0 cm; proximal–distal 2.5–4.0 cm

D. Variable without guideline

Correct answer: B

18. The immediate post-balloon adaptation period should be managed with:

A. High-dose opioids and fasting

B. Aggressive hydration, potent antiemetics, reassessment if symptoms persist beyond 7 days

C. Routine NSAIDs and delayed follow-up

D. No intervention unless severe pain

Correct answer: B

19. A key adoption barrier for DMR discussed in the lecture is:

A. Lack of endoscopes

B. Dependence on fluoroscopy and guidewires and device complexity

C. Need for open surgical access

D. Mandatory inpatient admission

Correct answer: B

20. A highlighted cultural element within SAGES that supports professional growth is:

A. Exclusivity and hierarchy

B. Non-collaborative competition

C. Inclusivity, merit-based recognition, and long-term leadership opportunities

D. Isolation of subspecialties

Correct answer: C

MOTIVATIONAL MESSAGE FROM DR. R. K. MISHRA

“Precision in minimally invasive care is earned in quiet practice—each measured step, each disciplined decision, and each safeguarded outcome is a promise kept to our patients.”

Wishing you steady judgment, unwavering discipline, and continual growth as you refine your skills and elevate patient safety in every procedure.